Ieq Capital LLC Has $2.88 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Ieq Capital LLC raised its stake in Twist Bioscience Co. (NASDAQ:TWST) by 21.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,034 shares of the company’s stock after acquiring an additional 10,800 shares during the quarter. Ieq Capital LLC owned about 0.10% of Twist Bioscience worth $2,883,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Van ECK Associates Corp lifted its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares in the last quarter. Signaturefd LLC boosted its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 5,886 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 2,216 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $116,783.20. Following the completion of the sale, the chief executive officer now directly owns 674,718 shares in the company, valued at $35,557,638.60. This represents a 0.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 37,180 shares of company stock worth $1,821,971. 3.01% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research reports. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Barclays set a $58.00 price target on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Trading Down 8.4 %

Shares of NASDAQ TWST opened at $41.31 on Friday. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company’s fifty day moving average is $48.10 and its 200-day moving average is $45.75. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -12.22 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the previous year, the company posted ($0.75) earnings per share. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. Equities research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.